Reported Earlier, Precigen Prices $30M Public Offering Of 35,294,118 Common Stock At $0.85/Share
Portfolio Pulse from Benzinga Newsdesk
Precigen has priced a $30 million public offering of 35,294,118 common stock at $0.85 per share. The proceeds will be used for advancing PRGN-2012 to regulatory approval, limited clinical development of other pipeline assets, and general corporate purposes. The funds, along with strategic reprioritization and existing cash, are expected to support operations into early 2025.
August 08, 2024 | 5:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen has announced a $30 million public offering at $0.85 per share. The proceeds will be used to advance PRGN-2012, other pipeline assets, and general corporate purposes. The funds are expected to support operations into early 2025.
The public offering provides significant funding for Precigen's key projects and operational needs, which is likely to be viewed positively by investors. The stock price may see a short-term boost due to the financial stability and progress in their pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100